Angiotensin-converting enzymes in skeletal muscle: Sentinel of blood pressure control and glucose homeostasis

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 9, Issue 2, 2008, Pages 75-88

  Dietze, Guenther J ^a,b   Henriksen, Erik J ^c  

^a Hypertension and Diabetes Unit   (Germany)

^b Klinikum Schwabing   (Germany)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotesin converting enzymes; Diabetes; Endothellal derived; Hypertension; Hypolarizing factor; Kinins; Nitric oxide; Skeletal muscle contraction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; KININ; BIOLOGICAL MARKER;

ADRENERGIC SYSTEM; ATHEROSCLEROSIS; AUTOCRINE EFFECT; BLOOD PRESSURE REGULATION; BLOOD VESSEL COMPLIANCE; BLOOD VOLUME; DIABETES MELLITUS; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HUMAN; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; KALLIKREIN KININ SYSTEM; MUSCLE EXERCISE; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARACRINE SIGNALING; PATHOGENESIS; PROTEIN DEGRADATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SKELETAL MUSCLE; SLOW MUSCLE FIBER; ANIMAL; BLOOD; BLOOD PRESSURE; ENERGY METABOLISM; ENZYMOLOGY; EXERCISE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; METABOLISM; MUSCLE CELL; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; AUTOCRINE COMMUNICATION; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; EXERCISE; HOMEOSTASIS; HUMANS; KININS; MUSCLE FIBERS; MUSCLE, SKELETAL; PARACRINE COMMUNICATION; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 47349125562     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2008.011     Document Type: Review

References (198)

1. Hudlicka O. Muscle blood flow: Its relation to muscle metabolism and function. Amsterdam: Swets and Zeitlinger BV 1973;115.
2. Newsholme EA. The regulation of intracellular and extracellular fuel supply during sustained exercise. Ann N Y Acad Sci 1977; 301:81-91.
3. McComas A. Skeletal muscle: Form and function. Human kinetics. Champaign Ill 1996;235
4. Gaskell W. On the tonicity of the heart and blood vessels. J Physiol 1880;3:48-75.
5. Golenhofen K. Skelettmuskel. In: Physiologie des Kreislaufs. Vol 1. Berlin: Springer Verlag; 1971;401
6. Bernard C. Liquide de l'organisme. Paris 1859;325.
7. Clifford PS, Hellsten Y. Vasodilatory mechanisms in contracting skeletal muscle. J Appl Physiol 2004;97:393-403.
8. Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 1998;49:235-61.
9. DeFronzo BA, Ferrannini E, Hendler R, Felig P, Wahren J. Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes 1983;32:35-45.
10. Galbo H. Hormonal and metabolic adaptation to exercise. New York:Thieme-Stratton 1983;25.
11. McGarry JD, Foster DW. Regulation of ketogenesis and clinical aspects of the ketotic state. Metabolism 1972;21:471-89.
12. Ahlborg GFP, Hagenfeldt L, Hendler R, Wahren J. Substrate turnover during prolonged exercise in man. Splanchnic and leg metabolism of glucose, free fatty acids, and amino acids. J Clin Invest 1974; 53:1080-90.
13. Wicklmayr M, Dietze G. Effect of continuously increasing concentrations of plasma ketone bodies on the uptake and oxidation of glucose by muscle in man. Eur J Clin Invest 1978;8:415-21.
14. Lassen N, Lindbjerg J, Munck O. Measurement of blood flow through skeletal muscle by intramuscular injection of xenon-133. Lancet 1964;1:686-89.
15. Wasserman DH, Cherrington AD. Hepatic fuel metabolism during muscular work: Role and regulation. Am J Physiol Endocrinol Metab 1991; 260:E811-E824.
16. Camacho RCGP, Davis SN, Wasserman DH. Glucoregulation during and after exercise in health and insulin-dependent diabetes. Exerc Sport Sci Rev 2005;33:17-23.
17. Prince FP, Hikida RS, Hagerman FC. Human muscle fiber types in power lifters, distance runners and untrained subjects. Pflugers Arch 1976;363:19-26.
18. Armstrong RB, Phelps RO. Muscle fiber type composition of the rat hindlimb. Am J Anat 1984;171:259-72.
19. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-9.
20. Owen O, Morgan A, Kemp H, Sullivan J, Herrera M, Cahill G. Brain metabolism during fasting. J Clin Invest 1967;46:1589-95.
21. Taegtmeyer H, Hems R, Krebs HA. Utilization of energy-providing substrates in the isolated working rat heart. Biochem J 1980; 186:701-11.
22. Vicaut E, Hou X. Arteriolar constriction and local renin-angiotensin system in rat microcirculation. Hypertens 1993;21:491-7.
23. Mitchell D, Yu J, Tyml K. Comparable effects of arteriolar and capillary stimuli on blood flow in rat skeletal muscle. Microvasc Res 1997;53:22-32.
24. Wahren J, Sato Y, Ostman J, Hagenfeldt L, Felig P. Turnover and splanchnic metabolism of free fatty acids and ketones in insulin-dependent diabetics at rest and in response to exercise. J Clin Invest 1984;73:1367-76.
25. Boden G, Jadali F. Effects of lipid on basal carbohydrate metabolism in normal men. Diabetes 1991;40:686-92.
26. Jones A, Woods DR. Skeletal muscle RAS and exercise performance. Int J Biochem Cell Biol 2003;35:855-66.
27. Krulewitz AH, Fanburg BL. Stimulation of bovine endothelial cell angiotensin-I-converting enzyme activity by cyclic AMP-related agents. J Cell Physiol 1986;129:147-50.
28. Lloyd CJ, Cary DA, Mendelsohn FA. Angiotensin converting enzyme induction by cyclic AMP and analogues in cultured endothelial cells. Mol Cell Endocrinol 1987;52:219-25.
29. Xavier-Neto J, Pereira AC, Junqueira ML, Carmona R, Krieger JE. Rat ACE promoter regulation by beta-adrenergics and cAMP in endothelium. Hypertens 1999;34:31-8.
30. Martin WH, 3rd, Murphree SS, Saffitz JE. Beta-adrenergic receptor distribution among muscle fiber types and resistance arterioles of white, red, and intermediate skeletal muscle. Circ Res 1989; 64:1096-105.
31. Rao RH. Effects of Ang II on insulin sensitivity and fasting glucose metabolism in rats. Am J Hypertens 1994;7:655-60.
32. Richey JM, Ader M, Moore D, Bergman RN. Ang II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol Endocrinol Metab 1999;277:E920-E926.
33. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese zucker rats. Hypertens 2001;38:884-90.
34. Story D, Ziogas J. Interaction of angiotensin II with noradrenergic transmission. Trends Pharmacol Sci 1987;8:269-71.
35. Saxena PR. Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems. J Cardiovasc Pharmacol 1992; 19:(Suppl 6):S80-S88.
36. Ward PE, Russell JS, Vaghy PL. Angiotensin and bradykinin metabolism by peptidases identified in skeletal muscle. Peptides 1995; 16:1073-8.
37. Schaufelberger M, Drexler H, Schieffer E, Swedberg K. ACE gene expression in skeletal muscle in patients with chronic heart failure. J Card Fail 1998;4:185-91.
38. Malendowicz SL, Ennezat PV, Testa M et al. Ang II receptor subtypes in the skeletal muscle vasculature of patients with severe congestive heart failure. Circulation 2000;102:2210-13.
39. Ferrario CM, Iyer SN. Ang-(1-7): A bioactive fragment of the renin-angiotensin system. Regul Pept 1998;78:13-18.
40. Stroth U, Unger T. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol 1999;33(suppl 1):S21-S28; discussion S41-S43.
41. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: A specific target for hypertension management. Am J Hypertens 1999; 12:S205-S213.
42. Goldstein MS. Humoral nature of the hypoglycemic factor of muscular work. Diabetes 1961;10:232-34.
43. Havivi E, Wertheimer HE. A muscle activity factor increasing sugar uptake by rat diaphragms in vitro. J Physiol 1964; 172:342-52.
44. Holloszy JO. Exercise-induced increase in muscle insulin sensitivity. J Appl Physiol 2005;99:338-43.
45. Mellander S, Johansson B. Control of resistance, exchange, and capacitance functions in the peripheral circulation. Pharmacol Rev 1968;20:117-96.
46. Berne RM, Rubio R, Dobson JG, Jr., Curnish RR. Adenosine and adenine nucleotides as possible mediators of cardiac and skeletal muscle blood flow regulation. Circ Res 1971;28:(suppl 1)115.
47. Dietze G, Wicklmayr M. Evidence for a participation of the kallikrein-kinin system in the regulation of muscle metabolism during muscular work. FEBS Lett 1977;74:205-08.
48. Vergauwen L, Hespel P, Richter EA. Adenosine receptors mediate synergistic stimulation of glucose uptake and transport by insulin and by contractions in rat skeletal muscle. J Clin Invest 1994; 93:974-81.
49. Dietze GJ, Wicklmayr M, Rett K, Jacob S, Henriksen EJ. Potential role of bradykinin in forearm muscle metabolism in humans. Diabetes 1996;45(suppl 1):S110-S114.
50. Han DH, Hansen PA, Nolte LA, Holloszy JO. Removal of adenosine decreases the responsiveness of muscle glucose transport to insulin and contractions. Diabetes 1998;47:1671-75.
51. Lynge J, Hellsten Y. Distribution of adenosine A1, A2a and A2b receptors in human skeletal muscle. Acta Physiol Scand 2000; 169:283-90.
52. Dumke CL, Kim J, Arias EB, Cartee GD. Role of kallikrein-kininogen system in insulin-stimulated glucose transport after muscle contractions. J Appl Physiol 2002;92:657-64.
53. Constable SH, Favier RJ, Uhl J, Holloszy JO. Bradykinin does not mediate activation of glucose transport by muscle contraction. J Appl Physiol 1986;61:881-4.
54. Shimojo N, Pickens TG, Margolius HS, Mayfield RK. Tissue kallikrein and bradykinin do not have direct insulin-like actions on skeletal muscle glucose utilization. Biol Chem Hoppe Seyler 1987; 368:1355-61.
55. Leighton B, Lozeman FJ, Vlachonikolis IG, Challiss RA, Pitcher JA, Newsholme EA. Effects of adenosine deaminase on the sensitivity of glucose transport, glycolysis and glycogen synthesis to insulin in muscles of the rat. Int J Biochem 1988;20:23-7.
56. Challiss RA, Richards SJ, Budohoski L. Characterization of the adenosine receptor modulating insulin action in rat skeletal muscle. Eur J Pharmacol 1992;226:121-8.
57. Hellsten Y, Maclean D, Radegran G, Saltin B, Bangsbo J. Adenosine concentrations in the interstitium of resting and contracting human skeletal muscle. Circulation 1998;98:6-8.
58. Langberg H, Bjorn C, Boushel R, Hellsten Y, Kjaer M. Exercise-induced increase in interstitial bradykinin and adenosine concentrations in skeletal muscle and peritendinous tissue in humans. J Physiol 2002;542:977-83.
59. Rett K, Wicklmayr M, Fink E, Maerker E, Dietze G, Mehnert H. Local generation of kinins in working skeletal muscle tissue in man. Biol Chem Hoppe Seyler 1989; 370:445-9.
60. Stebbins CL, Carretero OA, Mindroiu T, Longhurst JC. Bradykinin release from contracting skeletal muscle of the cat. J Appl Physiol 1990;69:1225-30.
61. Ballard HJ. The influence of lactic acid on adenosine release from skeletal muscle in anaesthetized dogs. J Physiol 1991; 433:95-108.
62. Paldino RL, Hyman C, Lenthal J. Bradykinin-induced increase in total and effective blood flow in skeletal muscle. Circ Res 1962; 11:847-50.
63. Kjellmer I, Odelram H. The effect of some physiological vasodilators on the vascular bed of skeletal muscle. Acta Physiol Scand 1965; 63:94-102.
64. Hyman C, Paldino RL. Influence of intravascular and topically administered bradykinin on microcirculation of several tissues. Bibl Anat 1967;9:38-45.
65. Proctor KG. Reduction of contraction-induced arteriolar vasodilation by adenosine deaminase or theophylline. Am J Heart Circ Physiol 1984;247:H195-H205.
66. Bjornberg J, Maspers M, Mellander S. Metabolic control of large-bore arterial resistance vessels, arterioles, and veins in cat skeletal muscle during exercise. Acta Physiol Scand 1989;135:83-94.
67. Yang HY, Erdos EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 1970;214:374-6.
68. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of ACE (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 1993;268:9496-503.
69. Ehlers MRW, Riordan JF. Angiotensin-converting enzyme. Biochemistry and molecular biology. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, diagnosis, and management. New York: Raven Press 1990;1217-231.
70. Gross SR, Kelly M. Ca++ inhibition of isoproterenol responses in mammalian skeletal muscle. J Pharmacol Exp Ther 1981; 217:271-7.
71. Boix F, Rosenborg L, Hilgenfeldt U, Knardahl S. Contraction-related factors affect the concentration of a kallidin-like peptide in rat muscle tissue. J Physiol 2002;544:127-36.
72. Shimojo N, Chao J, Chao L, Margolius HS, Mayfield RK. Identification and characterization of a tissue kallikrein in rat skeletal muscles. Biochem J 1987;243:773-8.
73. Figueroa CD, Dietze G, Muller-Esterl W. Immunolocalization of bradykinin b2 receptors on skeletal muscle cells. Diabetes 1996; 45(suppl 1):S24-S28.
74. Rabito SF, Minshall RD, Nakamura F, Wang LX. Bradykinin B2 receptors on skeletal muscle are coupled to inositol 1,4,5-trisphosphate formation. Diabetes 1996;45 (suppl 1):S29-S33.
75. Figueroa CD, Marchant A, Novoa U et al. Differential distribution of bradykinin B2-receptors in the rat and human cardiovascular system. Hypertens 2001;37:110-20.
76. McAllister RM. Endothelium-dependent vasodilation in different rat hindlimb skeletal muscles. J Appl Physiol 2003;94:1777-84.
77. Dietze G, Wicklmayr M. Effect of bradykinin on muscular glucose uptake in man (German). Klin Wochenschr 1977;55:357-8.
78. Busse R, Fleming I. Molecular responses of endothelial tissue to kinins. Diabetes 1996;45(Suppl 1):S8-S13.
79. Frossard M, Joukhadar C, Steffen G, Schmid R, Eichler HG, Muller M. Paracrine effects of ACE- and angiotensin-II-receptor- inhibition on transcapillary glucose transport in humans. Life Sci 2000; 66:PL147-PL154.
80. Wicklmayr M, Dietze G, Mayer L, Bottger I, Grunst J. Evidence for an involvement of kinin liberation in the priming action of insulin on glucose uptake into skeletal muscle. FEBS Lett 1979; 98:61-5.
81. Kishi K, Muromoto N, Nakaya Y et al. Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. Diabetes 1998;47:550-8.
82. Taguchi T, Kishikawa H, Motoshima H et al. Involvement of bradykinin in acute exercise-induced increase of glucose uptake and GLUT-4 translocation in skeletal muscle: Studies in normal and diabetic humans and rats. Metabolism 2000;49:920-30.
83. Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ. ACE inhibition and glucose transport in insulin-resistant muscle: Roles of bradykinin and nitric oxide. Am J Physiol Regul Integrative Comp Physiol 1999;277:R332-R336.
84. Henriksen EJ, Jacob S, Augustin HJ, Dietze GJ. Glucose transport activity in insulin-resistant rat muscle. Effects of angiotensin-converting enzyme inhibitors and bradykinin antagonism. Diabetes 1996;45(suppl 1):S125-S128.
85. Rett K, Jauch KW, Wicklmayr M, Dietze G, Fink E, Mehnert H. ACE inhibitors in diabetes: Experimental and human experience. Postgrad Med J 1986;62(suppl 1):59-64.
86. Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1987; 17:448-54.
87. Ekelund U. Effects of angiotensin-converting enzyme inhibition on arterial, venous and capillary functions in cat skeletal muscle in vivo. Acta Physiol Scand 1996;158:29-37.
88. Wright DC, Geiger PC, Holloszy JO, Han DH. Contraction-and hypoxia-stimulated glucose transport is mediated by a Ca2+-dependent mechanism in slow-twitch rat soleus muscle. Am J Physiol Endocrinol Metab 2005;288:E1062-E1066.
89. Kishi K, Hayashi H, Wang L et al. Gq-coupled receptors transmit the signal for GLUT-4 translocation via an insulin-independent pathway. J Biol Chem 1996;271:26561-8.
90. Cockcroft JR, Chowienczyk PJ, Brett SE, Bender N, Ritter JM. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol 1994;38:317-21.
91. Stiegler H, Rett K, Wicklmayr M, Dietze K, Mehnert H. Metabolic effects of prostaglandin E1 on human skeletal muscle. Vasa 1988; 17:5-9.
92. Ekelund U, Bjornberg J, Grande PO, Albert U, Mellander S. Myogenic vascular regulation in skeletal muscle in vivo is not dependent on endothelium-derived nitric oxide. Acta Physiol Scand 1992; 144:199-207.
93. Endo T, Imaizumi T, Tagawa T, Shiramoto M, Ando S, Takeshita A. Role of nitric oxide in exercise-induced vasodilation of the forearm. Circulation 1994;90:2886-90.
94. Duffy SJ, Tran BT, New G et al. Continuous release of vasodilator prostanoids contributes to regulation of resting forearm blood flow in humans. Am J Physiol Heart Circ Physiol 1998; 274:H1174-H1183.
95. Bradley SJ, Kingwell BA, McConell GK. Nitric oxide synthase inhibition reduces leg glucose uptake but not blood flow during dynamic exercise in humans. Diabetes 1999;48:1815-21.
96. Sarabi M, Lind L, Millgard J et al. Local vasodilatation with metacholine, but not with nitroprusside, increases forearm glucose uptake. Physiol Res 1999;48:291-5.
97. Honing ML, Smits P, Morrison PJ, Rabelink TJ. Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization. Hypertens 2000; 35:1314-18.
98. Inokuchi K, Hirooka Y, Shimokawa H et al. Role of endothelium-derived hyperpolarizing factor in human forearm circulation. Hypertens 2003;42:919-24.
99. Wilson JR, Kapoor SC. Contribution of prostaglandins to exercise-induced vasodilation in humans. Am J Physiol Heart Circ Physiol 1993; 265:H171-H175.
100. Green DJ, O'Driscoll G, Blanksby BA, Taylor RR. Control of skeletal muscle blood flow during dynamic exercise: Contribution of endothelium-derived nitric oxide. Sports Med 1996; 21:119-46.
101. Hickner RC, Fisher JS, Ehsani AA, Kohrt WM. Role of nitric oxide in skeletal muscle blood flow at rest and during dynamic exercise in humans. Am J Physiol Heart Circ Physiol 1997;273:H405-H410.
102. Duffy SJ, New G, Tran BT, Harper RW, Meredith IT. Relative contribution of vasodilator prostanoids and NO to metabolic vasodilation in the human forearm. Am J Physiol Heart Circ Physiol 1999; 276:H663-H670.
103. Karamouzis M, Langberg H, Skovgaard D, Bulow J, Kjaer M, Saltin B. In situ microdialysis of intramuscular prostaglandin and thromboxane in contracting skeletal muscle in humans. Acta Physiol Scand 2001; 171:71-6.
104. Kingwell BA, Formosa M, Muhlmann M, Bradley SJ, McConell GK. Nitric oxide synthase inhibition reduces glucose uptake during exercise in individuals with type 2 diabetes more than in control subjects. Diabetes 2002;51:2572-80.
105. Kalliokoski KK, Langberg H, Ryberg AK et al. Nitric oxide and prostaglandins influence local skeletal muscle blood flow during exercise in humans: Coupling between local substrate uptake and blood flow. Am J Physiol Regul Integr Comp Physiol 2006; 291:R803-R809.
106. Dietze G, Wicklmayr M, Mayer L, Bottger I, von Funcke H. Bradykinin and human forearm metabolism: Inhibition of endogenous prostaglandin synthesis. Hoppe Seylers Z Physiol Chem 1978;359:369-78.
107. Cockcroft JR, Chowienczyk PJ, Brett SE, Ritter JM. Effect of NG-monomethyl-l-arginine on kinin-induced vasodilation in the human forearm. Br J Clin Pharmacol 1994; 38:307-10.
108. O'Kane KP, Webb DJ, Collier JG, Vallance PJ. Local l-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. Br J Clin Pharmacol 1994;38:311-15.
109. Halcox JP, Narayanan S, Cramer-Joyce L, Mincemoyer R, Quyyumi AA. Characterisation of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am J Physiol Heart Circ Physiol 2001;280:H2470-H2477.
110. Schrage WG, Dietz NM, Eisenach JH, Joyner MJ. Agonist-dependent variability of contributions of nitric oxide and prostaglandins in human skeletal muscle. J Appl Physiol 2005;98:1251-7.
111. Moncada S, Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
112. Etgen GJ, Jr Fryburg DA, Gibbs EM. Nitric oxide stimulates skeletal muscle glucose transport through a calcium/contraction- and phosphatidyl-inositol-3-kinase-independent pathway. Diabetes 1997;46:1915-19.
113. Balon TW, Nadler JL. Evidence that nitric oxide increases glucose transport in skeletal muscle. J Appl Physiol 1997; 82:359-63.
114. Young ME, Radda GK, Leighton B. Nitric oxide stimulates glucose transport and metabolism in rat skeletal muscle in vitro. Biochem J 1997;322:223-8.
115. Hardie DG, Carling D. The AMP-activated protein kinase. Fuel gauge of the mammalian cell? Eur J Biochem 1997;246:259-73.
116. Higaki Y, Hirshman MF, Fujii N, Goodyear LJ. Nitric oxide increases glucose uptake through a mechanism that is distinct from the insulin and contraction pathways in rat skeletal muscle. Diabetes 2001; 50:241-7.
117. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;97:2601-10.
118. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994;94:2511-15.
119. Baron AD. The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium-derived nitric oxide. Diabetes 1996;45(suppl 1):S105-S109.
120. Wunsch SA, Muller-Delp J, Delp MD. Time course of vasodilatory responses in skeletal muscle arterioles: Role in hyperemia at onset of exercise. Am J Physiol Heart Circ Physiol 2000;279:H1715-H1723.
121. Kilbom A, Wennmalm A. Endogenous prostaglandins as local regulators of blood flow in man: Effect of indomethacin on reactive and functional hyperaemia. J Physiol 1976;257:109-21.
122. Frandsen U, Bangsbo J, Langberg H, Saltin B, Hellsten Y. Inhibition of nitric oxide synthesis by systemic NG-monomethyl-l-arginine administration in humans: Effects on interstitial adenosine, prostacyclin and potassium concentrations in resting and contracting skeletal muscle. J Vasc Res 2000;37:297-302.
123. Sun D, Huang A, Smith CJ, Stackpole CJ et al. Enhanced release of prostaglandins contributes to flow-induced arteriolar dilation in eNOS knockout mice. Circ Res 1999;85:288-93.
124. Godecke A, Schrader J. Adaptive mechanisms of the cardiovascular system in transgenic mice. Lessons from eNOS and myoglobin knockout mice. Basic Res Cardiol 2000;95:492-8.
125. Leighton B, Budohoski L, Lozeman FJ, Challiss RA, Newsholme EA. The effect of prostaglandins E1, E2 and F2-alpha and indomethacin on the sensitivity of glycolysis and glycogen synthesis to insulin in stripped soleus muscles of the rat. Biochem J 1985;227:337-40.
126. Nesher R, Karl IE, Kipnis DM. Dissociation of effects of insulin and contraction on glucose transport in rat epitrochlearis muscle. Am J Physiol Cell Physiol 1985;249:C226-C232.
127. Leighton B, Challiss RA, Newsholme EA. The role of prostaglandins as modulators of insulin-stimulated glucose metabolism in skeletal muscle. Horm Metab Res Suppl 1990;22:89-95.
128. Zorzano A, Balon TW, Jakubowski JA, Goodman MN, Deykin D, Ruderman NB. Effects of insulin and prior exercise on prostaglandin release from perfused rat muscle. Evidence that prostaglandins do not mediate changes in glucose uptake. Biochem J 1986;240:437-43.
129. Dietze G, Wicklmayr M, Bottger I, Mayer L. Insulin action on glucose uptake into skeletal muscle: Inhibition of endogenous biosynthesis of prostaglandins. FEBS Lett 1978;92:294-8.
130. Begum N, Tepperman HM, Tepperman J. Studies on the possible involvement of prostaglandins in insulin generation of pyruvate dehydrogenase activator. Diabetes 1985;34:29-37.
131. Dietze GJ. Modulation of the action of insulin in relation to the energy state in skeletal muscle tissue: Possible involvement of kinins and prostaglandins. Mol Cell Endocrinol 1982;25:127-49.
132. Haddy FJ, Vanhoutte PM, Feletou M. Role of potassium in regulating blood flow and blood pressure. Am J Physiol Regul Integr Comp Physiol 2006;290:R546-R552.
133. Feletou M, Vanhoutte PM. The third pathway: Endothelium-dependent hyperpolarization. J Physiol Pharmacol 1999;50:525-34.
134. Popp R, Brandes RP, Ott G, Busse R, Fleming I. Dynamic modulation of interendothelial gap junctional communication by 11,12-epoxyeicosatrienoic acid. Circ Res 2002;90:800-06.
135. Boushel R, Langberg H, Gemmer C et al. Combined inhibition of nitric oxide and prostaglandins reduces human skeletal muscle blood flow during exercise. J Physiol 2002;543:691-8.
136. Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 1996;94:3341-7.
137. Fleming I, Hecker M, Busse R. Intracellular alkalinization induced by bradykinin sustains activation of the constitutive nitric oxide synthase in endothelial cells. Circ Res 1994;74:1220-6.
138. Huang A, Sun D, Carroll MA et al. EDHF mediates flow-induced dilation in skeletal muscle arterioles of female eNOS-ko mice. Am J Physiol Heart Circ Physiol 2001;280:H2462-H2469.
139. Bergaya S, Matrougui K, Meneton P, Henrion D, Boulanger CM. Role of tissue kallikrein in response to flow in mouse resistance arteries. J Hypertens 2004;22:745-50.
140. Scotland RS, Madhani M, Chauhan S et al. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: Key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation 2005;111:796-803.
141. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Endothelial dysfunction in hypertension. J Cardiovasc Pharmacol 2001; 38(suppl 2):S11-S14.
142. van Zwieten PA, de Jonge A. Interaction between the adrenergic and renin-angiotensin-aldosterone-systems. Postgrad Med J 1986; 62(suppl 1):23-7.
143. Schwieler JH, Kahan T, Nussberger J, Hjemdahl P. Converting enzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechanisms. Am J Physiol Endocrinol Metab 1993; 264:E631-E637.
144. Chowienczyk PJ, Watts GF, Cockcroft JR, Bitter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992;340:1430-2.
145. Celermajer DS, Adams MR, Clarkson P et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996;334:150-4.
146. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994;24:471-6.
147. Corretti MC, Plotnick GD, Vogel RA. The effects of age and gender on brachial artery endothelium-dependent vasoactivity are stimulus-dependent. Clin Cardiol 1995;18:471-6.
148. Butler R, Morris AD, Burchell B, Struthers AD. DD-angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans. Hypertens 1999;33:1164-8.
149. Caballero AE, Arora S, Saouaf R et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999;48:1856-62.
150. Dzau VJ, Bernstein K, Celermajer D et al. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88:L1-L20.
151. Ghiadoni L, Magagna A, Versari D et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertens 2003;41:1281-6.
152. Jambrik Z, Sebastiani L, Picano E, Ghelarducci B, Santarcangelo EL. Hypnotic modulation of flow-mediated endothelial response to mental stress. Int J Psychophysiol 2005;55:221-7.
153. O'Neill MS, Veves A, Zanobetti A et al. Diabetes enhances vulnerability to particulate air pollution-associated impairment in vascular reactivity and endothelial function. Circulation 2005; 111:2913-20.
154. Ishibashi Y, Takahashi N, Shimada T et al. Short duration of reactive hyperemia in the forearm of subjects with multiple cardiovascular risk factors. Circ J 2006;70:115-23.
155. Wicklmayr M, Rett K, Fink E et al. Bradykinin is not liberated by working skeletal muscle in diabetes type II. Horm Metab Res 1989;21:222-3.
156. Wicklmayr M, Rett K, Fink E et al. Kinins are not liberated by working skeletal muscle in the majority of patients with essential hypertension. Horm Metab Res 1989;21:292-3.
157. Dorin RI, Field JC, Boyle PJ, Eaton RP, Icenogle MV. Insulin resistance limits glucose utilization and exercise tolerance in myophosphorylase deficiency and NIDDM. J Appl Physiol 1996;81:1273-8.
158. Belke DD, Swanson EA, Dillmann WH. Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 2004;53:3201-08.
159. Brassard P, Ferland A, Gaudreault V, Bonneville N, Jobin J, Poirier P. Elevated peak exercise systolic blood pressure is not associated with reduced exercise capacity in subjects with type 2 diabetes. J Appl Physiol 2006;101:893-7.
160. Stewart KJ, Sung J, Silber HA et al. Exaggerated exercise blood pressure is related to impaired endothelial vasodilator function. Am J Hypertens 2004;17:314-20.
161. Egan BM, Greene EL, Goodfriend TL. Insulin resistance and cardiovascular disease. Am J Hypertens 2001;14:S116-S125.
162. Cersosimo E, Defronzo RA. Insulin resistance and endothelial dysfunction: The road map to cardiovascular diseases. Diabetes Metab Res Rev 2006;22:423-36.
163. Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest 2006;116:1756-60.
164. Franklin SS. Hypertension in older people: Part 1. J Clin Hypertens (Greenwich) 2006;8:444-9.
165. Vogel RA, Corretti MC, Plotnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1996;77:37-40.
166. Ziccardi P, Nappo F, Giugliano G et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105:804-09.
167. Ribeiro MM, Silva AG, Santos NS et al. Diet and exercise training restore blood pressure and vasodilatory responses during physiological maneuvers in obese children. Circulation 2005;111:1915-23.
168. Williams IL, Chowienczyk PJ, Wheatcroft SB et al. Endothelial function and weight loss in obese humans. Obes Surg 2005; 15:1055-60.
169. Rehill N, Beck CR, Yeo KR, Yeo WW. The effect of chronic tobacco smoking on arterial stiffness. Br J Clin Pharmacol 2006;61:767-73.
170. Henriksen EJ, Jacob S. ACE inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes Metab 2003;5:214-22.
171. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 2004;30:498-505.
172. Pfeffer MA, Frohlich ED. Improvements in clinical outcomes with the use of ACE inhibitors: Cross-fertilization between clinical and basic investigation. Am J Physiol Heart Circ Physiol 2006; 291:H2021-H2025.
173. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-92.
174. Squire IB, O'Kane KP, Anderson N, Reid JL. Bradykinin B2-receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertens 2000;36:132-6.
175. Cervenka L, Maly J, Karasova L et al. Angiotensin II-induced hypertension in bradykinin B2-receptor knockout mice. Hypertens 2001;37:967-73.
176. Duka I, Shenouda S, Johns C, Kintsurashvili E, Gavras I, Gavras H. Role of the B2-receptor of bradykinin in insulin sensitivity. Hypertens 2001;38:1355-60.
177. Madeddu P, Emanueli C, Gaspa L et al. Role of the bradykinin B2-receptor in the maturation of blood pressure phenotype: Lesson from transgenic and knockout mice. Immunopharmacology 1999; 44:9-13.
178. Damas J, Bourdon V, Lefebvre PJ. Insulin sensitivity, clearance and release in kininogen-deficient rats. Exp Physiol 1999; 84:549-57.
179. Xiong W, Chao J, Chao L. Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertens 1995; 25:715-19.
180. Montanari D, Yin H, Dobrzynski E et al. Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes 2005; 54:1573-80.
181. Mullins JJ, Ganten D. Transgenic animals: New approaches to hypertension research. J Hypertens Suppl 1990;8:S35-S37.
182. Langheinrich M, Lee MA, Bohm M, Pinto YM, Ganten D, Paul M. The hypertensive REN-2 transgenic rat TG(mREN2)27 in hypertension research. Characteristics and functional aspects. Am J Hypertens 1996; 9:506-12.
183. Blendea MC, Jacobs D, Stump CS et al. Abrogation of oxidative stress improves insulin sensitivity in the REN-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab 2005;288:E353-E359.
184. Kinnick TR, Youngblood EB, O'Keefe MP, Saengsirisuwan V, Teachey MK, Henriksen EJ. Modulation of insulin resistance and hypertension by voluntary exercise training in the TG(mREN 2)27 rat. J Appl Physiol 2002;93:805-12.
185. Sloniger JA, Saengsirisuwan V, Diehl CJ et al. Defective insulin signaling in skeletal muscle of the hypertensive TG(mREN 2)27 rat. Am J Physiol Endocrinol Metab 2005;288:E1074-E1081.
186. Henriksen EJ, Jacob S. Effects of captopril on glucose transport activity in skeletal muscle of obese zucker rats. Metabolism 1995;44:267-72.
187. Steen MS, Foianini KR, Youngblood EB, Kinnick TR, Jacob S, Henriksen EJ. Interactions of exercise training and ACE- inhibition on insulin action in obese zucker rats. J Appl Physiol 1999;86:2044-51.
188. Jarrett RJ. Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease. Chicken, egg or neither? Diabetologia 1984;26:99-102.
189. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
190. DeFronzo BA, Ferranini F. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardio-vascular disease. Diabetes Care 1991; 14:173-94.
191. Taegtmeyer H. Insulin resistance and atherosclerosis. Common roots for two common diseases? Circulation 1996;93:1777-9.
192. Hecquet C, Tan F, Marcic BM, Erdös EG. Human bradykinin receptor is activated by kallikrein and other serine proteases. Mol Pharmacol 2000;58:828-36.
193. Biyashev D, Tan F, Chen Z et al. Kallikrein activates bradykinin B2-receptors in the absence of kininogen. Am J Physiol Heart Circ Physiol 2006;290:H1244-H1250.
194. Erdös EG, Jackman HL, Brovkovych V, Tan F, Deddish PA. Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J Mol Cell Cardiol 2002;34:1569-76.
195. Chen Z, Fan F, Erdös EG, Deddish PA. Hydrolysis of angiotensin peptides by human ACE and the resensitation of B2 kinin receptors. Hypertens 2005;46:1368-73.
196. Nguyen G. Renin/prorenin receptors. Kidney Int 2006; 69:1503-06.
197. Danser AH, Saris JJ. Prorenin uptake in the heart: a prerequisite for local angiotensin generation? J Mol Cell Cardiol 2002; 34:1463-72.
198. Zhang X, Xie YW, Nasjletti A, Xu X, Wolin MS, Hintze TH. ACE-inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation 1997;95:176-82.